Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Phase II Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma Patients

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01182142

Enrollment

Registered

2010-08-16

Start date

2007-09-30

Completion date

2010-08-31

Last updated

2010-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Renal Cell Carcinoma

Brief summary

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. The role of capecitabine in treatment of metastatic renal cell carcinoma is discussed. In this trial, we are evaluating efficacy of capecitabine in metastatic renal cell carcinoma patients.

Interventions

DRUGCapecitabine

1,250 mg/m2 orally twice a day, days 1-14

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* histologically confirmed non-clear cell renal cell carcinoma * confirmed metastatic sites * no chemotherapy in history

Exclusion criteria

* metastases in CNS * previous targeted therapy * other tumor

Design outcomes

Primary

Measure	Time frame
Overall response rate	12 months

Secondary

Measure	Time frame
Overall survival Progression-free survival	24 months

Countries

Russia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026